Bellicum Pharmaceuticals (NASDAQ: BLCM) has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bottom (starting Aug 2019 to current) and with very successful … [Read more...] about BLCM #VolatilityWatch
FDA
Biotech: Time To Buy the Bull
As the month of October begins and broader markets sold off, biotech stocks are still largely negative and/ or flat for the year. As seen in the LABU vs. LABD chart below, the spread between the two … [Read more...] about Biotech: Time To Buy the Bull
INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review
Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read more...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review
Pdufa Watch
Nabriva's Hype It has been decades since the US has seen a new novel treatment in the antibiotics arena, creating positive sentiment surrounding the approval of Nabriva's Contepo (fosfomycin). … [Read more...] about Pdufa Watch
Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish
You must be logged in to post a comment.